Elutia Inc Class A ELUT

Boston Scientific released the full $8 million holdback on schedule and with no claimsEscrow release is the third funding catalyst Elutia has delivered in 2026, following the August closings of its Avenue Capital loan facility and SimpliDerm® divestitureThe Company is now fully funded through the first year of the expected NXT-41x launch and into 2029 GAITHERSBURG, Md., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix t

GAITHERSBURG, Md., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer; Dr. Michelle Williams, Chief Scientific Officer; and Matthew Ferguson, Chief Financial Officer, will present and host one-on-one meetings with investors at the H.C. Wainwright 28th Annual Global Investment Conference at the Lotte New York Palace Hotel in New York City on Septe

GAITHERSBURG, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer, Matthew Ferguson, Chief Financial Officer, and Dr. Michelle Williams, Chief Scientific Officer, will participate in two upcoming investor conferences. Lake Street Capital Markets 10th Annual Big Ideas Growth ConferenceElutia will host one-on-one meetings with investors at the

Acquisition expands Cellution Biologics’ human tissue-based portfolio and marks its entry into the U.S. reconstructive surgery marketROSWELL, Ga., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Cellution Biologics Inc. (“Cellution Biologics” or the “Company”), a biologics company focused on developing, manufacturing and commercializing advanced human tissue-based products, today announced the completion of its acquisition of the SimpliDerm hydrated human acellular dermal matrix (ADM) business from Elutia Inc

Deal valued at $11 million in cash, with $8 million at closing and up to $3 million in additional milestone payments over the next 18 monthsDivestiture further concentrates Elutia’s attention and resources on the development and commercialization of NXT-41x NXT-41x is an antibiotic-eluting biomatrix designed to address post-operative infection in the $1.5 billion U.S. plastic and reconstructive surgery market NXT-41x clearance expected in the first half of 2027 GAITHERSBURG, Md., Aug. 18, 2026 (

Moby summary of Elutia Inc.'s Q2 2026 earnings call

Elutia Inc (ELUT) reports Q2 2026 results, highlighting robust surgeon interest in NXT41X and a strengthened balance sheet despite a slight revenue dip.

Independent Blinded Survey of 50 Plastic Surgeons Validates Demand; NXT-41 and NXT-41x Remain On-TrackFunded through launch: secured up to $26 million of capital without an equity offeringThe unmet need is real: 86% of surgeons surveyed say the matrices they use today increase infection riskThe demand is strong: 96% of surgeons surveyed are interested in adopting NXT-41x; 92% responded they would champion it at their hospital value analysis committeeOn track: NXT-41 FDA clearance decision expect

$10 million funded at closing; second $5 million tranche unlocked upon FDA 510(k) clearance of NXT-41xPreserves shareholder value by funding commercialization of Elutia's next-generation antibiotic-eluting biomatrix without an equity offeringNXT-41x targets the 15–20% post-operative infection rates in multiple complex plastic and reconstructive surgical procedures GAITHERSBURG, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-elutin

GAITHERSBURG, Md., July 31, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its second quarter 2026 financial results after market close on Thursday, August 13, 2026. Members of the Company’s management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following

Acquisition marks Cellution Biologics' entry into the U.S. reconstructive surgery market through an established human acellular dermal matrix platform.SimpliDerm® expands Cellution Biologics' advanced biologics portfolio beyond wound care, ocular repair, and other surgical applications into reconstructive surgery.Transaction supports Cellution Biologics' long-term strategy of building a global biologics platform while ensuring continuity of supply for existing customers. ROSWELL, Ga., July 16, 2

Transaction provides $8 million in cash at closing and up to $3 million in technology transfer and commercial milestone payments over the next 18 monthsProceeds provide additional non-dilutive capital to advance NXT-41x toward anticipated clearance and targeted commercial launch in 2027Divestiture sharpens Elutia’s focus on NXT-41x and the $1.5 billion plastic and reconstructive surgery opportunity GAITHERSBURG, Md., July 16, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “

How Elutia's drug-eluting biomatrix technology is targeting post-surgical infection in implant-based breast reconstruction — and the unmet need driving that mission. GAITHERSBURG, Md., June 11, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer, and Dr. Michelle Williams, Chief Scientific Officer, will present and host one-on-one meetings with investors at

Elutia Inc (ELUT) reports a 6% increase in total net sales and significant progress in its NXT-41 regulatory program, despite challenges in SimpliDerm revenue and increased net loss.

NXT-41 review advancing collaboratively with FDA, informing NXT-41x submission preparationsBrought a new automated manufacturing process online, supporting a gross margin target of more than 80% at scaleChief Commercial Officer Pete Ligotti's initial surgeon engagement confirming significant unmet need and market opportunityStrong balance sheet with $36.5 million in cash and escrowed proceeds from the BioEnvelope business divestitureConference call today at 5:00 p.m. ET / 2:00 p.m. PT GAITHERSBU